An overview of vaccine development for COVID-19

Seyed H Shahcheraghi; Jamshid Ayatollahi; Alaa Aa Aljabali; Madhur D Shastri; Shakti D Shukla; Dinesh K Chellappan; Niraj K Jha; Krishnan Anand; Naresh K Katari; Meenu Mehta; Saurabh Satija; Harish Dureja; Vijay Mishra; Abdulmajeed G Almutary; Abdullah M Alnuqaydan; Nitin Charbe; Parteek Prasher; Gaurav Gupta; Kamal Dua; Marzieh Lotfi; Hamid A Bakshi; Murtaza M Tambuwala

doi:10.4155/tde-2020-0129

An overview of vaccine development for COVID-19

Seyed H Shahcheraghi, Jamshid Ayatollahi, Alaa Aa Aljabali, Madhur D Shastri, Shakti D Shukla, Dinesh K Chellappan, Niraj K Jha, Krishnan Anand, Naresh K Katari, Meenu Mehta, Saurabh Satija, Harish Dureja, Vijay Mishra, Abdulmajeed G Almutary, Abdullah M Alnuqaydan, Nitin Charbe, Parteek Prasher, Gaurav Gupta, Kamal Dua, Marzieh LotfiHamid A Bakshi, Murtaza M Tambuwala

Research output: Contribution to journal › Article › peer-review

55 Citations (Scopus)

288 Downloads (Pure)

Abstract

The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines - peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus - are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.

Original language	English
Pages (from-to)	235-244
Number of pages	10
Journal	Therapeutic Delivery
Volume	12
Issue number	3
Early online date	24 Feb 2021
DOIs	https://doi.org/10.4155/tde-2020-0129
Publication status	Published (in print/issue) - 24 Feb 2021

Bibliographical note

Publisher Copyright:
© 2021 Future Medicine Ltd.. All rights reserved.

Keywords

COVID-19
COVID-19 vaccines
SARS-CoV-2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4155/tde-2020-0129

tde-2020-0129 (1)Author Accepted Manuscript, 689 KB
tde-2020-0129Final published version, 1.04 MBLicence: CC BY

Cite this

Shahcheraghi, S. H., Ayatollahi, J., Aljabali, A. A., Shastri, M. D., Shukla, S. D., Chellappan, D. K., Jha, N. K., Anand, K., Katari, N. K., Mehta, M., Satija, S., Dureja, H., Mishra, V., Almutary, A. G., Alnuqaydan, A. M., Charbe, N., Prasher, P., Gupta, G., Dua, K., ... Tambuwala, M. M. (2021). An overview of vaccine development for COVID-19. Therapeutic Delivery, 12(3), 235-244. https://doi.org/10.4155/tde-2020-0129

@article{9d26aca0e60248728aacb1dcfee4f2bd,

title = "An overview of vaccine development for COVID-19",

abstract = "The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines - peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus - are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.",

keywords = "COVID-19, COVID-19 vaccines, SARS-CoV-2",

author = "Shahcheraghi, {Seyed H} and Jamshid Ayatollahi and Aljabali, {Alaa Aa} and Shastri, {Madhur D} and Shukla, {Shakti D} and Chellappan, {Dinesh K} and Jha, {Niraj K} and Krishnan Anand and Katari, {Naresh K} and Meenu Mehta and Saurabh Satija and Harish Dureja and Vijay Mishra and Almutary, {Abdulmajeed G} and Alnuqaydan, {Abdullah M} and Nitin Charbe and Parteek Prasher and Gaurav Gupta and Kamal Dua and Marzieh Lotfi and Bakshi, {Hamid A} and Tambuwala, {Murtaza M}",

year = "2021",

month = feb,

day = "24",

doi = "10.4155/tde-2020-0129",

language = "English",

volume = "12",

pages = "235--244",

journal = "Therapeutic Delivery",

issn = "2041-5990",

publisher = "Future Science Group",

number = "3",

}

Shahcheraghi, SH, Ayatollahi, J, Aljabali, AA, Shastri, MD, Shukla, SD, Chellappan, DK, Jha, NK, Anand, K, Katari, NK, Mehta, M, Satija, S, Dureja, H, Mishra, V, Almutary, AG, Alnuqaydan, AM, Charbe, N, Prasher, P, Gupta, G, Dua, K, Lotfi, M, Bakshi, HA & Tambuwala, MM 2021, 'An overview of vaccine development for COVID-19', Therapeutic Delivery, vol. 12, no. 3, pp. 235-244. https://doi.org/10.4155/tde-2020-0129

TY - JOUR

T1 - An overview of vaccine development for COVID-19

AU - Shahcheraghi, Seyed H

AU - Ayatollahi, Jamshid

AU - Aljabali, Alaa Aa

AU - Shastri, Madhur D

AU - Shukla, Shakti D

AU - Chellappan, Dinesh K

AU - Jha, Niraj K

AU - Anand, Krishnan

AU - Katari, Naresh K

AU - Mehta, Meenu

AU - Satija, Saurabh

AU - Dureja, Harish

AU - Mishra, Vijay

AU - Almutary, Abdulmajeed G

AU - Alnuqaydan, Abdullah M

AU - Charbe, Nitin

AU - Prasher, Parteek

AU - Gupta, Gaurav

AU - Dua, Kamal

AU - Lotfi, Marzieh

AU - Bakshi, Hamid A

AU - Tambuwala, Murtaza M

PY - 2021/2/24

Y1 - 2021/2/24

N2 - The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines - peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus - are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.

AB - The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines - peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus - are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.

KW - COVID-19

KW - COVID-19 vaccines

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85103265556&partnerID=8YFLogxK

U2 - 10.4155/tde-2020-0129

DO - 10.4155/tde-2020-0129

M3 - Article

C2 - 33624533

SN - 2041-5990

VL - 12

SP - 235

EP - 244

JO - Therapeutic Delivery

JF - Therapeutic Delivery

IS - 3

ER -

An overview of vaccine development for COVID-19

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this